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In recent years, an emerging role of YAP and TAZ in the 
increasingly sophisticated cancer biology field demands a more articulate 
understanding of protein networks surrounding YAP and TAZ. This also 
means elucidation of detailed regulatory mechanisms relevant to 
YAP/TAZ within the pre-established signaling pathway, is crucial to 
better understand the extent of YAP and TAZ’s activity during cancer 
development. 
With this in mind, I worked on candidate regulatory partners of YAP 
and TAZ.  SGK1 is an oncoprotein of the PI3-K signaling pathway 
with recent therapeutic implication in AKT inhibitor-resistant cancers. I 
confirmed that SGK1 is a downstream target of YAP with rapid 
responsiveness to YAP activation. Moreover, SGK1 transcription was 
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controlled by a critical YAP-interacting transcription factor, TEAD. In 
addition, I found that YAP directly binds to the distal enhancer of 
SGK1 to promote transcription. On the other hand, I discovered that 
SGK1 controls canonical YAP/TAZ targets, CTGF and CYR61 via its 
kinase domain and PPxY motif. Furthermore, SGK1 regulates YAP and 
TAZ protein levels to promote CTGF and CYR61 expression. Lastly, I 
found that SGK1 stabilizes TAZ via GSK3β phosphorylation.          
Alternatively, I discovered that TAZ is regulated by its paralog, YAP, 
in a negative way. I found that this regulation is rather unidirectional 
and conserved among numerous cell lines. TAZ regulation by YAP was 
controlled at the translational level, but not at the transcriptional or 
post-translational level. Finally, I found this regulatory mechanism was 
independent of the Hippo signaling pathway. 
In conclusion, I discovered two regulatory mechanisms controlling TAZ 
in both positive and negative manners.
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INTRODUCTION
The Hippo pathway is a universally conserved tumor suppressor 
pathway conserved from flies to human. Originally identified in 
Drosophila, Hippo of the Hippo pathway is a tumor-suppressive 
upstream kinase of Warts, which is the other tumor-suppressive 
upstream kinase of Yorkie, the transcriptional regulator. Overexpression 
of Yorkie in Drosophila wing disc resulted in uncontrolled overgrowth, 
while promoted cell proliferation and anti-apoptosis in eye disc, 
suggesting an oncogenic role of Yorkie. (Huang et al., 2005) The 
mammalian homologs of Yorkie, YAP and TAZ are the effector 
molecules of the Hippo pathway that controls organ size, tissue 
regeneration upon injury and cancer development. (Harvey et al., 2013; 
Johnson and Halder, 2014). Due to their role in the initiation and the 
progression of cancer in many types of organs, YAP and TAZ are 
implicated in cancer therapy (Janse van Rensburg et al., 2016; 
Zanconato et al., 2016a).
Until recent, YAP and TAZ are shown to be solely regulated by their 
upstream kinases, LATS1 and LATS2, reflecting the canonical Hippo 
dependent regulation on YAP and TAZ. For example, Hippo signaling 
is activated by basolateral polarity organizing proteins such as Scribble 
in high cell density context and inactivated by GPCR (G-Protein 
coupled Receptor) upon a serum stimulation (Condenonsi et al., 2011; 
Yu et al., 2012). However, intriguing works by Piccolo and colleagues 
showed the Hippo pathway independent regulation of YAP and TAZ by 
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transducers of mechanical signals (Dupont et al., 2011, Aragona et al., 
2013). This opened up the discussion on the regulation of YAP and 
TAZ in the Hippo pathway independent mechanism.
Although YAP and TAZ are highly expressed in cancers of many 
organs, Hippo upstream regulators are rarely mutated in human cancers, 
while mutations in NF2 or LATS1 or LATS2 were present in only 
certain tumor histotypes (Harvey et al., 2013; Zanconato et al., 2016b). 
This suggested additional mode of YAP/TAZ regulation may be 
involved in YAP and TAZ driven cancers. Not surprisingly, recent 
works uncovered cooperative relations of the Hippo pathway with Wnt, 
TGFβ, Notch, mevalonate, and EGF signaling (Hansen et al., 2015; 
Zhou et al., 2016).
In following studies, I worked on uncovering hidden branches of 
regulatory mechanisms of YAP and TAZ. Surprisingly, I discovered a 
dual role of SGK1 as a downstream target gene of YAP, and positive 
regulator of YAP and TAZ. Moreover, I also worked on regulatory 
relations of YAP and TAZ. I found that YAP regulates TAZ in 
unidirectional mode, while this regulation is controlled at the 
translational level via a LATS1/2 independent mechanism.
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CHAPTER I




The importance of YAP/TAZ in the field of tissue regeneration and 
cancer necessitates the discovery of their new regulatory partners. 
Initially identified as a homolog of AKT in PI3K signaling, SGK1 acts 
as a serine/threonine protein kinase in multiple oncogenic pathways.
However, the possible link between SGK1 and YAP/TAZ oncoproteins 
remains unexplored. Here, I investigated whether SGK1 serves as a 
positive regulator of YAP/TAZ, utilizing a standard molecular cell 
biology approach. Indeed, SGK1 levels are positively correlated with 
levels of YAP/TAZ target genes, CTGF and CYR61 in MCF-10A cells. 
Mechanistically, SGK1 elevates YAP/TAZ protein levels to enhance 
their activity. As I investigated further, I found that SGK1 stabilizes 
TAZ via SGK1-GSK3ß-TAZ inhibitory circuit. I also accumulated 
evidence that YAP controls SGK1 expression, retrospectively. 
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Introduction
YAP (Yes-Associated　 Protein) is an oncogenic transcriptional 
coactivator. YAP was first identified as a protein that contains a protein 
interaction motif called the WW domain (Sudol et al., 1995). Studies 
thereafter revealed that YAP is a transcriptional coactivator which binds 
transcription factors for enhancement of transcriptional output (Yagi et 
al., 1999). Therefore, the physiological functions of YAP depend on 
which transcription factor it binds to.  Suggesting its versatility, YAP 
not only has a WW domain, but also has TEAD-binding, PDZ-binding, 
SH3 domain-binding motifs (Wang et al., 2009). 
As a proto-oncogene found in the 11q22 amplicon that is frequently 
observed in multiple human cancers, YAP promotes invasion and 
proliferation, inhibits apoptosis and is sufficient for to cause cellular 
transformation (Overholtzer et al., 2006). Likewise, TAZ (Transcriptional 
coactivator with PDZ binding motif), a paralog of YAP, is known to 
have similar functions as YAP in terms of cell proliferation, 
anti-apoptosis, and cell-transforming property (Chan et al., 2008).  Both 
YAP and TAZ are mammalian homologs of Yorkie, the downstream 
effector protein of newly emerging tumorsuppressor pathway called the 
Hippo pathway (Zhao et al., 2010). The Hippo pathway has been 
shown to be conserved in many metazoan species ranging from 
Drosophila to mammals. Therefore, understanding the function and 
regulatory partners of YAP and TAZ may provide important insights to 
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an evolutionarily conserved regulatory mechanism of cell proliferation 
and cell survival. 
SGK1 (Serum- and glucocorticoid inducible kinase 1) belongs to the 
AGC family of serine/threonine protein kinases, which also includes 
AKT1 (protein kinase B) and protein kinase C as well as SGK1’s close 
paralogs, SGK2 and SGK3. As one can tell from its name, SGK1 level 
is regulated by serum and glucocorticoids, in addition to various stimuli 
(Waldegger et al., 1997, Leong et al., 2003). SGK1’s enzymatic activity 
is controlled by a phosphorylation cascade initiated by PI3K 
(Phosphoinositide-3 kinase) activation, and executed by PDKs 
(Phosphoinositide-dependent protein kinases).
Recently, Drosophila genetics study suggested that Yorkie, the 
Drosophila homolog of YAP and TAZ, positively regulates dAkt (Ye et 
al., 2012). dAkt is an oncogenic kinase induced by insulin and is a 
Drosophila homolog of a mammalian protein kinases, AKT1 and SGK1, 
with which it shares high sequence similarity. Intriguingly, both SGK1 
and AKT1 phosphorylate and control the activity of many of the same 
target proteins (Wu et al., 2004, Aoyama et al., 2005). Both AKT1 and 
SGK1 are known to promote cell proliferation, and cell survival (Brunet 
et al. 2001, Bruhn et al. 2010). Even though AKT1 and SGK1 have 
these similarities, they differ in their functional domain. For example, 
AKT1 contains a PH (Pleckstrin Homology) domain that is required for 
the PI3K-dependent plasma membrane localization, while SGK1 does 
not have a PH domain which explains why SGK1 may remain active 
in the absence of PIP3 (Castel et al., 2016). Therefore, distinguishing 
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features of SGK1 and AKT1 suggests an additional layer of complexity 
we researchers should be aware of when considering therapeutic options 
in AKT or SGK1-activated cancers. 
The similarity between aforementioned AKT1 or SGK1 activation and 
the phenotype observed by YAP overexpression, with the above fly 
genetics data, suggests that AKT1 or SGK1 could be a compelling 
target of YAP induced tumorigenesis in mammals. However, evidence 
of whether SGK1 could be regulated analogously by YAP as dAkt by 
Yorkie in Drosophila remains lacking.
Next, there are similarities between YAP and SGK1.  First, SGK1 is 
involved in multiple oncogenic signaling cascades, including the mTOR 
and PI3K signaling pathway (Park et al., 1999, Hong et al., 2008), 
while recent studies suggested a crosstalk between YAP-Hippo pathway 
and mTOR/PI3K pathway (Tumaneng et al., 2012, Mo et al., 2015). In 
addition, while SGK1 was initially identified as protein kinase 
upregulated by serum (Webster et al., 1993), YAP and TAZ were 
recently shown to be activated upon stimulation with serum (Yu et al., 
2012). However, the possible link between SGK1 and YAP/TAZ 
onco-proteins remains unexplored. It would be interesting to find out 
whether a regulatory relationship exists between SGK1 and the 
YAP/TAZ-Hippo pathway.
In this study, I found that SGK1 is a downstream target gene of 
YAP. The TEAD binding motif of YAP was responsible for controlling 
SGK1 transcriptional expression. In addition, YAP directly binds to 
SGK1 enhancer region which contains the TEAD consensus motif, 
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CATTCC. Physiologically, SGK1 supports YAP function in anchorage 
independent growth. On the other hand, SGK1 positively regulates 
YAP/TAZ. SGK1 enhances YAP/TAZ target genes, CTGF and CYR61. 
More interestingly, SGK1 up-regulates YAP and TAZ levels. SGK1 
stabilizes TAZ protein by inhibition of SGK1 substrate, GSK3β, which 
also happens to be a negative regulator of TAZ. These data suggests 
SGK1 is a novel positive regulator of YAP/TAZ.
7
Materials and Methods
Cell culture and Drug treatments
MCF-10A was cultured in DMEM/F12 media supplemented with 5% 
horse serum, 20 ng/ml EGF, 0.5 μg/ml hydrocortisone, 100 ng/ml 
cholera toxin, 10 μg/ml and insulin as completed medium. 293T and 
HEK293 were cultured in DMEM supplemented with 10% FBS. All of 
these media contained antibiotics (penicillin/streptomycin). In case of 
SGK1 knockdown sets, cells were split to reach confluence at the time 
of harvest, while for SGK1 overexpression experiments, cells were split 
to stay sub-confluence when YAP/TAZ are active.
For drug treatments, the following compounds and concentrations were 
used: MG132 (50　μM, 6　h), GSK650394 (1　μM, 2.5　μM, 5　μM, 24　
h), Lithium Chloride (25　mM, 24　h), BIO (8 μM, 24　h)
Lentiviral SGK1 Overexpression plasmids
pCMV-SGK1 plasmid was a kind gift from Dr. Eui-Ju Choi. WT 
SGK1 was cloned into pLVX IRES puro (purchased from Addgene) by 
BamH1. Kinase-dead SGK1, K127R SGK1 and WW domain binding 
defective SGK1, Y298A SGK1 were generated by nested PCR 
technique.
Primers used for SGK1 mutation are following: K127R SGK1 Forward 
(5-ATGCAGTCAAGGTTTTACAGA-3), K127R SGK1 Reverse (5-TCT 
GTA AAA CCT TGA CTG CAT-3), Y298A SGK1 Forward 
(5-GCCTGCCGCCTTTTGCTAGCCGAAACACAG-3) and Y298A SGK1 
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Reverse (5-CTGTGTTTCGGCTAGCAAAAGGCGGCAGGC-3). To 
generate lentivirus, pLVX IRES puro SGK1, pCMV-dR8.2 dvpr and 
pCMV-VSVG were transfected into 293T cells with polyethyleneimine. 
After 6-hour incubation, initial medium was changed to fresh medium, 
and incubated for 48 h. On the harvest day, lentiviral supernatant was 
collected to be infected into target cell line with polybrene (9　μg/ml). 
After a day, viral supernatant was replaced to normal medium.  
shRNA infection and shRNA sequences 
To produce retroviruses, pSuper retro (puro), pCMV-Gag-Pol and 
pCMV-VSVG were transfected into 293T cells with polyethyleneimine. 
Two days later, the media were harvested and centrifuged for 20 min 
at 3,000 g. For retrovirus infection, the harvested media were added 
into the same volume of normal culture media with polybrene (9 
μg/ml), cultured for 24 h and replaced with a normal culture medium. 
Two days after the infection, puromycin(0.5　 μg/ml) was added for 
selection. pSuper retro shGFP and pSuper retro shSGK1 A were gifted 
from Dr. Eui-ju Choi (Kim et al., 2007). shSGK1 is shSGK1 A, 
otherwise indicated.
shRNA sequences used in this study are shGFP 
(5-GGCUACGUCCAGGAGCGCACC-3), shSGK1 A
(5-GTCCTTCTCAGCAAATCAACC-3) and shSGK1 B
(5-CGGAATGTTCTGTTGAAGAA-3). shSGK1 B sequence was obtained 
from Sommer et al. (Sommer et al., 2013) which has TRC number of 
TRCN0000194957. 
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siRNA transfection and siRNA sequnces
Lipofectamine RNAiMAX Reagent (Life Technologies) was used for 
transfection of siRNA. siRNA was prepared and transfected as described 
by the manufacturer. RNA oligonucleotides were synthesized by 
Samchully Pharmaceutical Co. siRNA sequences used in this study are 
siControl(GL2) (5-CGTACGCGGAATACTTCGA-3), siYAP 
(5-GACAUCUUCUGGUCAGAGA-3), and siTAZ (5-ACGUUG 
ACUUAGGAACUUU-3). siYAP and siTAZ sequences were obtained 
from Kim et al. (Kim et al., 2015b). 
Retrovirus generation for YAP 5SA Overexpression
pMSCV hygro, pMSCV hygro flag 5SA YAP and pMSCV hygro flag 
5SA S94A YAP plasmid were used for control or 5SA or 5SA　S94A 
YAP overexpression experiments. Plasmids were transfected into 293T 
cells to produce retroviruses used for target cell infection. 
Western blot 
Cells were harvested and lysed with RIPA buffer (50 mM Tris-Cl pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 
0.1% SDS) containing protease inhibitors and phosphatase inhibitors (1 
μg/ml Pepstatin A, 1 μg/ml Leupeptin, 1 mM Phenylmethylsulfonyl 
Fluoride, 1 mM Sodium Orthovanadate, 5 mM Sodium Fluoride). 
Western blot analyses were performed using a standard protocol. 
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Quantitative PCR 
RNA preparation and cDNA synthesis were done as described by the 
manufacturer using RiboEx (GeneAll) and M-MLV reverse transcriptase 
(Enzynomics). Quantitative polymerase chain reaction (qPCR) was 
performed using a SYBR green premix reagent (TOPreal qPCR 2X 
PreMIX; Enzynomics) and Bio-Rad CFX Connect instrument. Results 
were analyzed using Microsoft Excel.
Primers used for quantitative PCR are following:
GAPDH Forward (5-CTTCGCTCTCTGCTCCTCCT-3), GADPH Reverse 
(5-GTTAAAAGCAGCCCTGGTGA-3), SGK1 Forward 
(5-CATATTATGTCGGAGCGGAATGT-3), SGK1 Reverse 
(5-TGTCAGCAGTCTGGAAAGAGA-3), CTGF Forward 
(5-CCAATGACAACGCCTCCTG-3), CTGF Reverse 
(5-TGGTGCAGCCAGAAAGCTC-3), CYR61 Forward 
(5-GGTCAAAGTTACCGGGCAGT-3), CYR61 Reverse 
(5-GGAGGCATCGAATCCCAGC-3), YAP Foward 
(5-GAACCAGAGAATCAGTCAGA-3), YAP Reverse 
(5-GGATTGATATTCCGCATTGC-3), TAZ Forward 
(5-GTCCTACGACGTGACCGAC-3), and TAZ Reverse 
(5-CACGAGATTTGGCTGGGATAC-3).
Antibodies
Antibodies used for western blot analysis include: YAP (raised against 
the C-terminal human YAP antigen by Kim et al. (Kim et al. 2015)), 
SGK1 (D27C11) (Cell Signaling Tech.), CTGF (Santa Cruz Biotech.), 
11
CYR61 (Santa Cruz Biotech.), ß-actin (Sigma), p-YAP (Ser127) (Cell 
Signaling Tech.), TAZ (Cell Signaling Tech.), p-GSK3α/β (Cell 
Signaling Tech.), and Ubiquitin (Santa Cruz Biotech.), LATS2 (Cell 
Signaling Tech.), and GSK3α/β (Cell Signaling Tech).
Luciferase assay 
Luciferase constructs and each indicated DNA construct were 
co-transfected with a Renilla luciferase construct, used as a control for 
transfection efficiency. Luciferase assays were performed using the 
Dual-Luciferase Reporter Assay System (Promega) following the 
manufacturer’s guide. Luciferase signal intensities were calculated 
relative to those of Renilla luciferase using Microsoft Excel. 
in vivo ubiquitination assay
In vivo ubiquitination assay was performed in high stringency IP 
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P40, 
0.5% sodium deoxycholate) with 0.1% SDS to dissociate TAZ 
interacting proteins from TAZ during ubiquitination reaction. For 
immunoprecipitation of TAZ, anti-TAZ antibody (Santa Cruz Biotech.) 
was used instead of anti-TAZ antibody (Cell Signaling Tech.) due to 
stronger binding affinity.
Chromatin Immunoprecipitation
Two confluent 100-mm culture dishes (2~3x107 cells) were washed 
with PBS and DNA of these cells were cross-linked with 1% 
12
formaldehyde for 15 minutes. Cells were then processed for ChIP assay 
as previous described by Kim et al. (Kim et al. 2015c) using anti-Flag 
antibody (Sigma F1804) (5 μg) and Protein A/G agarose (GenDEPOT) 
(20 μl). Relative enrichment in SGK1 regulatory sequences and CTGF 
promoters were measured as a ratio to enrichment in the gene desert in 
chromosome 12. 
The following primers were used to detect the indicated genomic 
regions:
SGK1 7807 ChIP Forward (5-CTGCACCAGGGAAAATGC-3), SGK1 
7807 ChIP Reverse (5-GATTTGGCTTTTCTTTGACCA-3), CTGF ChIP 
Forward (5-CAATCCGGTGTGAGTTGATG-3), CTGF ChIP Reverse 
(5-GCCAATGAGCTGAATGGAGT-3), Gene Desert 12 ChIP Forward 
(5-TTCCAAGCGGTAAAGCTTC-3), and Gene Desert 12 ChIP Reverse 
(5-TCCCAAAGTGCTGGGATTAC-3). Sequences for Gene desert 12 
were obtained from Kim et al. (Kim et al., 2015c). 5SA YAP was 
used for optimal binding to chromatin.
Gene Expression Omnibus (GEO) microarray analysis
Microarray data for YAP hyperactive overexpression was downloaded 
from NCBI GEO. Microarray data was normalized and analyzed with 
Morpheus (Broad Institute). The Microarray used for this study is 
GSE60579 (Kim et al. 2015). 
ChIP sequencing (GEO and unpublished) analysis 
Raw and processed ChIP sequencing data for overexpressed YAP 
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enrichment in the genome was downloaded from NCBI GEO. ChIP 
sequencing data were uploaded onto UCSC genome browser 
(http://Genome.ucsc.edu/). The ChIP sequencings used for this study 
were GSE61852 (Stein et al. 2015) and unpublished ChIP sequencing 
data by Dr. Dae-Sik Lim (KAIST). 
Soft agar assay
Cell culture grade agar (Sigma) was dissolved in sterile water using a 
microwave. Bottom agar in media (0.5% agar) was plated in the wells 
of a 6-well plate. Trypsinized cells (2x104 cells per well) were then 
suspended in pre-warmed top agar in media (0.4% agar), then plated 
atop the bottom agar. Medium (2 ml per well) was changed to fresh 
medium every day, and incubated for 18 days. Colonies were stained 
with crystal violet. Images were acquired for one random region per 
well. The number and size of colonies were analyzed using the ImageJ 
program.
Statistical analysis 
Two-tailed t-tests were used for statistical analyses. All analyses were 
performed using Prism4 (GraphPad Software). Error bars indicate 




SGK1 is a bona fide downstream target of YAP in MCF-10A cells.
Initially, I started my investigation searching for a putative relationship 
between SGK1 and YAP, by noticing that SGK1 was a candidate YAP 
target gene. Kim et al. previously performed a microarray analysis of 
MCF-10A-overexpressing Estrogen Receptor Domain (ERt2) fused-YAP 
2SA (YAP with intermediate level of hyper-activation), so that YAP 
target genes would readily respond upon administration of the Estrogen 
analog, 4-Hydrooxytamoxifen (Kim et al., 2015c). From analyzing 
SGK1 gene expression profile at early time points of 
4-Hydrooxytamoxifen treatment, I noticed that SGK1 very readily 
responded to the estrogen analog, as early as 2 h post-treatment. SGK1 
was identified as an immediate early gene to serum and glucocorticoid 
(Webster et al., 1993). Thus, I found that SGK1 as one of genes that 
was quickly and strongly upregulated by YAP (Figure1.1A). Moreover, 
other groups’ microarray data including that of Kim et al., consistently 
suggested SGK1 as a candidate YAP signature gene, by showing 
increase of SGK1 expression by approximately 3- to 5-fold in response 
to overexpression of various forms of YAP in mouse livers, mouse 
fibroblasts, and human mammary epithelial cells (Figure 1.1B) (Dong et 
al., 2007, Zhao et al., Kim et al., 2015c).
   In order to confirm that SGK1 is a bona fide downstream target of 
YAP, I overexpressed various forms of YAP, each known to have
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Figure 1-1. Numerous studies suggest SGK1 as a candidate downstream 
target of YAP.
(A) Heat-map analysis of SGK1 in MCF-10A ERt2-YAP2SA microarray 
by Kim et al. (Kim et al., 2015). GSE60579 by Kim et al. was 
normalized and selected for a gene corresponding to SGK1.  
(B) Three independent groups showing that SGK1 is increased upon 
overexpression of different forms of YAP.
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altered activities. I overexpressed WT YAP, 5SA YAP that is known 
thus far to be most hyperactive, S94A YAP that is TEAD transcription 
factor binding deficient (thus inactive due to inability to bind to DNA), 
and 5SA S94A YAP that is TEAD-binding deficient and thus no longer 
hyperactive (Zhao et al., 2008). Using Western blot and Quantitative 
real time PCR, I observed that SGK1 was somewhat significantly 
increased by WT YAP overexpression while 5SA YAP dramatically 
increased SGK1 in both protein and transcript levels, where a similar 
pattern could be observed in canonical YAP target genes, CTGF and 
CYR61 (Figure 1.2A-B). On the other hand, SGK1 upregulation was 
abolished to a nearly basal state level in both S94A YAP and S94A 
5SA YAP (Figure 1.2A-B). These data point to two things: First, 
SGK1 expression by YAP is synchronized to other well-known YAP 
target genes, CTGF and CYR61. Second, SGK1 transcript and protein 
levels are tightly affected by YAP’s ability to form the TEAD-YAP 
transcription factor-coactivator complex, which is known to be the most 
critical transcription factor affecting YAP activity (Zhao et al., 2008).  
Collectively, our data strongly support that SGK1 is a valid downstream 
target of YAP and this transcriptional control is TEAD-dependent. 
To more closely examine the relationship between SGK1 and YAP 
relationship, I tried to figure out whether YAP amplifies SGK1 
transcript directly or indirectly. Although evidence for immediate SGK1 
response to YAP activation suggests that SGK1 is directly regulated by 
YAP, it was not conclusive. Thus, I searched for clues as to whether 
YAP is enriched in the SGK1 promoter region. Kim et al. (Kim et al., 
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Figure 1-2. YAP hyperactivity drastically increases SGK1 in a TEAD 
dependent manner.
(A) Western blot analysis of SGK1 and YAP targets in stable cell lines 
that were generated by infecting either Control Vector or YAP 
packaged retroviruses (WT, S94A, 5SA, 5SA S94A) into MCF-10A and 
later selected with puromycin. 
(B) Quantitative PCR analysis of SGK1 and YAP target genes in same 
sets as in (A). Each gene was normalized to GAPDH.
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2015c) recently performed YAP Chromatin Immunoprecipitation 
Sequencing in MCF-10A cells (Unpublished data), from which I 
decided to search for SGK1 chromatin region for YAP-binding peaks.  
Unfortunately, I could not detect a statistically significant YAP peak 
near the SGK1 transcription start site. However, I did see significant 
YAP peaks in SGK1 regulatory sequences in the chromatin. The 
regulatory sequences of a particular gene may consist of not only the 
promoter, but also enhancer region. I found there were three significant 
YAP peak intervals in the SGK1 regulatory sequence region marked by 
oranage lines (Figure 1.3). Among them, the YAP peak I named 7807, 
is approximately 120 kb away from the nearest SGK1 transcript variant, 
and approximately 250 kb away from the SGK1 TSS (Transcription 
start site). YAP peak 7807 showed the strongest peak intensity among 
the three YAP peaks (Figure 1.3). 
There has been a few recent papers that suggested that YAP binds to 
enhancer regions of most target genes and activates them by chromatin 
looping (Zanconato et al., 2015, Galli et al., 2015, Stein et al., 2015). 
YAP peak 7807 region fits into this criterion as an enhancer region. 
Surprisingly, independent YAP ChIP sequencing data from Bauer group 
(Stein et al., 2015) showed the strongest YAP peak in the 
approximately the same region as YAP peak 7807 of SGK1 genomic 
region in three different cell lines they analyzed (Figure 1.4). The three 
cell lines they used were: IMR90 which is non-transformed human 
fibroblast, and the other two were SF268 and NCI-H2052, cancer cell 
lines of brain and lung, respectively (Stein et al., 2015).  Therefore, a 
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Figure 1-3. YAP ChIP sequencing result indicates YAP is enriched in 
region “7807” of distal SGK1 regulatory sequences. 
SGK1 regulatory sequences in line with YAP bound regions. YAP 
ChIP-sequencing data (raw and significant peaks) (Unpublished data 
provided by Dr. Dae-Sik Lim) were loaded into UCSC genome browser 




Figure 1-4. Region “7807” is enriched by YAP in non-transformed and 
transformed cells.
YAP peak 7807 is correlated with YAP ChIP-seq peaks in IMR90, 
NCI-H2052, and SF268.  YAP ChIP-seq data were downloaded from 
NCBI GEO (GSE61852) (Stein et al., 2015). 
Then, YAP ChIP-seq data for each cell line were uploaded into UCSC 
genome browser.  Orange rectangles indicate three YAP ChIP-seq peaks 




total of four different YAP ChIP sequencing results indicate that not 
only YAP binds to SGK1 regulatory sequences but also that YAP peak 
7807 may be specific region where YAP is potentially enriched.
As a next step, I decided to validate whether the peak 7807 is where 
YAP authentically binds to SGK1 regulatory sequences. First, I checked 
the reliability of our ChIP-qPCR analysis by confirming that YAP binds 
to the CTGF promoter region. As predicted, YAP bound to the CTGF 
promoter region as previously reported (Figure 1.5A) (Zhao et al., 
2008). More importantly, our ChIP-qPCR indicated YAP directly bound 
to peak 7807 in the genome (Figure 1.5A).  Interestingly, when I 
observed more closely the genomic sequences of YAP peak 7807, I 
found two DNA binding consensus sequences for TEAD, CATTCC 
(Figure 1.5B). This finding hints that YAP, which cannot directly bind 
to DNA, may bind to YAP peak 7807 genomic region by forming a 
complex with TEAD transcription factor. All these data are consistent 
with the hypothesis that YAP regulates SGK1 transcriptional 
upregulation by direct binding to SGK1 regulatory sequences with 
TEAD.
Next, I　 investigated whether TEAD　 transcription factor could bind to 
the putative SGK1 enhancer, 7807. When Bauer group’s TEAD1 ChIP 
seq. (GSE61852) were analyzed, I found the strongest TEAD1　peak in 
region 7807 of the SGK1 regulator sequences, suggesting that both 
YAP　and TEAD　may cooperatively bind to the SGK1 enhancer, 7807 
(Figure 1.6).  
   Since I found that both YAP and TEAD　bind to SGK1 enhancer 
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Figure 1-5. YAP directly binds to region “7807.”
(A) YAP ChIP-qPCR analysis of gene desert, CTGF promoter and 
7807(the SGK1 enhancer) in 5SA YAP overexpressed MCF-10A. 5SA 
YAP was used for maximum YAP enrichment in the nucleus. Data are 
means ±SD; *P<0.05; **P<0.01.
(B) Genomic sequences of the SGK1 enhancer region 7807. There are 
two TEAD consensus binding motif (CATTCC) in the sequence.
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Figure 1-6. TEAD1 binds to region “7807.”
TEAD1 ChIP-seq analysis of SF268 cell line. TEAD1 ChIP-seq data 
were downloaded from NCBI GEO (GSE61852) and then uploaded onto 
UCSC genome browser. The arrow indicates region 7807 identified 
from YAP ChIP-seq of MCF-10A that is also TEAD1 bound. Histine 3 




region 7807,　I wanted to test whether this binding is actually functional 
in YAP mediated SGK1 transcription. To do so, I designed SGK1 
luciferase reporter construct that mimics the SGK1 genomic region. My 
firefly luciferase construct consisted of SGK1 promoter region near the 
SGK1 Transcriptional start site and YAP peak region 7807 located in 
the enhancer position placed behind the Luciferase (Figure 1.7A). If 
YAP really bound to the enhancer region of SGK1 and promotes 
SGK1 transcription by chromatin looping, my aforementioned SGK1 
reporter construct should be responsive to YAP overexpression. To 
validate the above notion was actually reliable, I transfected hyperactive 
5SA YAP or TEAD binding deficient 5SA94A with my SGK1 reporter 
construct. Upon overexpression of 5SA YAP, I found an approximately 
3~4 fold increase in SGK1 reporter activity, consistent with the 
hypothesis that YAP controls SGK1 transcription by YAP binding to 
the SGK1 enhancer region 7807 (Figure 1.7B). Furthermore, consistent 
with my previous results, YAP that cannot bind to TEAD failed to 
activate the SGK1 reporter, signifying the importance of TEAD 
transcription factor in SGK1 transcription. These data support that YAP 
binding to SGK1 genomic region is a functionally significant event.
Next, I wanted to examine the functional significance of SGK1 
transcription by YAP. YAP confers oncogenic property to cells upon 
overexpression, and therefore, I hypothesized that SGK1 transcription by 
YAP has an additive role in YAP’s oncogenic function. Along this 
line, SGK1 was recently recognized to be important in 
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Figure 1-7. YAP increases SGK1 reporter activity in a TEAD-dependent 
manner.
(A) Schematic diagram of SGK1 luciferase reporter mimicking SGK1 
genomic region.
(B) SGK1 reporter markedly responded to 5SA YAP overexpression, 
but not in 5SA 94A YAP. SGK1 luciferase reporter constructs were 
transfected into HEK293 cells in combination with YAP mutants and 
renilla luciferase. Cells were harvested after 24 h and luciferase signals 
were measured by laminator. Firefly luciferase activity was normalized 
by Renilla luciferase.  Data are means ±SD; ***P<0.001.
32
33
anchorage-independent growth, which mimics metastatic cancer cell 
survival in unfavorable conditions (Mason et al., 2016). Thus, I 
predicted that both YAP and SGK1 may be functional for growth in 
harsh environments. In order to test this, I performed a soft agar assay 
using 5SA YAP or 5SA YAP with SGK1-depleted MCF-10A. As 
expected, SGK1 knockdown in YAP 5SA-overexpressing MCF-10A 
significantly reduced colony size (Figure 1.8). This result implies that 
SGK1 is required for anchorage-independent growth in YAP activated 
MCF-10A. 
SGK1 enhances YAP/TAZ activity in MCF-10A cells.
While analyzing literature, I incidentally came across primary articles 
that indicated SGK1 controls CTGF, which is a well-known downstream 
target of YAP/TAZ (Vallon et al., 2006, Hussain et al., 2008, Zhao et 
al., 2008, Zhang et al., 2009). These reports hinted at the possibility of 
SGK1 controlling YAP/TAZ activity. Therefore, to investigate whether 
SGK1 can positively affect YAP/TAZ, I quantified levels of YAP/TAZ 
target genes upon SGK1 knockdown in MCF-10A. I chose CTGF and 
CYR61, since they are representative target genes of YAP and TAZ. 
When I measured mRNA levels of CTGF and CYR61, their levels 
were significantly reduced and positively correlated to SGK1 
knockdown status (Figure 1.9A). Before performing gain of function 
experiments, I generated mutant SGK1 forms by nested PCR. SGK1 
has two notable regulatory amino acid residues that are
34
Figure 1-8.  SGK1 is required for anchorage-independent growth 
property of YAP over-expressing MCF-10A. 
(A)　Colony formation assay in MCF-10A cells stably expressing 5SA 
YAP with either shGFP or shSGK1. Magnified view of representative 
colonies in each type of stable cell line stained with crystal violet and 
imaged with a dissecting microscope.
(B) Quantification of average colony size and number of colonies for 
the results in (A). *P<0.05.
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Figure 1-9.  SGK1 enhances YAP/TAZ target genes, CTGF and 
CYR61. 
(A) Quantitative PCR analysis of MCF-10A cells stably expressing 
control verses shSGK1. Data are means ±SD; *P<0.05; **P<0.01.
(B) Schematic of SGK1 mutants used in the study containing ATP 
binding motif and PY motif.
(C) Quantitative PCR analysis of MCF-10A cells stably expressing 
either vector or Flag-SGK1 (WT, K127R, and Y298A). Data are means 
±SD; *P<0.05; **P<0.01. ***P<0.001.
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important for its activity (Figure 1.9B). One is Lysine 127, which is 
the ATP-binding site of SGK1 kinase domain, and when mutated to 
arginine, SGK1 loses its kinase activity. Therefore, K127R site is 
critical for SGK1 kinase activity (Synder et al., 2002). The other site is 
Tyrosine 298, of its part of PPxY motif, which mediates protein-protein 
interaction with WW-domain containing proteins such as NEDD4 and 
NEDD4L E3 ubiquitin ligases (Synder et al., 2002). When this Tyrosine 
residue is substituted to Alanine, WW domain containing proteins lose 
affinity to SGK1, and therefore, SGK1 from its potential substrates. 
Then reciprocally, I decided to evaluate the transcript levels of CTGF 
and CYR61 in SGK1 over-expressed MCF-10A. Upon WT SGK1 
overexpression, there was a significant increase in levels of CTGF and 
CYR61 which was positively correlated to SGK1 level while CTGF and 
CYR61 levels in SGK1 mutant overexpressing cells were significantly 
reduced compared to that of WT SGK1 (Figure 1.9C). From the above 
results, I can infer that SGK1 kinase activity and its binding affinity to 
WW domain-containing proteins may have a regulatory role in SGK1 
control of YAP/TAZ target gene levels.
Next, to examine whether SGK1 controls activity of YAP-TEAD 
complex, I assessed 8x-TEAD binding sequence (TBS) reporter activities 
upon SGK1 overexpression in HEK293 cells. 8x-TBS reporter assay has 
previous been shown to be a reliable YAP-TEAD reporter (Kim et al., 
2015a). Parallel to previous results, WT SGK1 overexpression increased 
YAP-TEAD activity while the activity was relatively reduced upon 
overexpression of either K127R SGK1 or Y298A SGK1 (Figure 1.10A). 
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Figure 1-10.  SGK1 enhances YAP-TEAD reporter activity via its 
PPxY motif and Kinase domain.
(A) Dual Reporter Luciferase analysis of HEK293 cells transiently 
transfected with different forms of SGK1 (WT, K127R, Y298A). Three 
independent experiments were performed to detect 8x TBS reporter 
activity. *P<0.05. Data are means ±SD.
(B) Dual Reporter Luciferase analysis of HEK293 cells transiently 
transfected in combination of WT YAP and various SGK1 constructs. 
Data are means ±SD.
(C) Dual reporter luciferase analysis of HEK293 cells transiently 
transfected with WT YAP and treated with SGK1 inhibitor, 
GSK650394. Data are means ±SD.
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Furthermore, co-overexpression of WT YAP and WT SGK1 
synergistically reinforced YAP-TEAD reporter activity compared to 
single overexpression of WT YAP (Figure 1.10B). Meanwhile, TEAD 
activities measured upon overexpression of SGK1 mutants (K127R or 
Y298A) confirmed that these residues are important for cooperation 
between YAP and SGK1 for YAP-TEAD activity (Figure 1.10B). 
Alternatively, I treated SGK1 inhibitor, GSK650394, on WT YAP 
overexpressed HEK293 cells. GSK650394 is a competitive small 
molecule inhibitor of SGK1 and has previously been shown to block 
prostate cancer cell growth (Sherk et al., 2008). As predicted, I 
confirmed that SGK1 activity was important for WT YAP induced 
increase in YAP-TEAD activity (Figure 1.10C). These data suggest that 
SGK1 kinase activity and SGK1 PPxY motif were important for SGK1 
mediated synergism on YAP-TEAD activity.
SGK1 enhances YAP/TAZ activity by upregulation of YAP/TAZ in 
MCF-10A cells.
Knowing that SGK1 enhances transcriptional levels of CTGF and 
CYR61, I next analyzed the protein levels of CTGF and CYR61 upon 
SGK1 knockdown in MCF-10A. In concurrence with analysis of CTGF 
and CYR61 mRNA levels, CTGF and CYR61 protein levels were 
down-regulated upon SGK1 knockdown (Figure 1.11A). More 
surprisingly, when I observed the protein levels of YAP and TAZ, their 
levels were down-regulated and positively correlated with CTGF
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Figure 1-11.  SGK1 increases YAP and TAZ protein levels.
(A) MCF-10A cells each stably expressing shGFP or shSGK1 A or 
shSGK1 B was analyzed by Western blot with various antibodies. 
(B) MCF-10A cells treated with GSK650394 (DMSO as a vehicle) for 
24 h were analyzed by Western blot with various antibodies. 
(C) MCF-10A cells each stably expressing Vector, WT SGK1, K127R 




and CYR61 levels (Figure 1.11A). This observation led us to 
hypothesize that SGK1 regulates YAP/TAZ to control their target genes. 
Interestingly, phospho-YAP (Ser127), a critical phosphorylation site for 
YAP activity and YAP cytoplasmic localization as previously reported 
(Zhao et al., 2008), was not upregulated by SGK1 knockdown, meaning 
that SGK1 mediated upregulation of YAP/TAZ is LATS kinase activity 
independent (Figure 1.11A). In order to confirm SGK1-mediated 
upregulation of YAP/TAZ, I treated SGK1 inhibitor, GSK650394 in 
MCF-10A and observed for changes in YAP/TAZ　 activity to SGK1 
kinase inactivation. In agreement with SGK1 knockdown results, SGK1 
inhibitor treatment led to not only reduction of CTGF and CYR61 
levels, but also, reduction in YAP and TAZ (Figure 1.11B). Again, 
phospho-YAP (Ser127) was not significantly affected by SGK1 
inhibitor, indicating that SGK1 mediated positive regulation of 
YAP/TAZ and their activities are independent from YAP 
phosphorylation on Serine 127. I then looked at the effects of SGK1 
overexpression in YAP/TAZ and their target genes. Consistent with our 
previously shown transcript analyses, WT SGK1 increased CTGF and 
CYR61 protein levels while kinase dead K127R SGK1 and PPxY motif 
mutated Y298A SGK1 each decreased CTGF and CYR61 comparable 
to basal state levels (Figure 1.11C). As previously mentioned, 
phospho-YAP levels were not correlated with SGK1 levels, suggesting 
that SGK1 controls YAP irrespective of Serine 127 phosphorylation. 
Our previously shown loss of function and gain of function experiments 
uniformly indicate SGK1 as a positive regulator of YAP/TAZ and their 
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target genes.
In order to ensure that SGK1 upregulation of CTGF and CYR61 are 
YAP/TAZ-dependent, I ablated the levels of both YAP and TAZ in 
SGK1 overexpressing MCF-10A cells. When I analyzed both protein 
levels and mRNA levels of upon YAP/TAZ knockdown in SGK1 
overexpressing set, CTGF and CYR61 were drastically reduced, 
implying that YAP/TAZ lie downstream of SGK1 in controlling levels 
of CTGF and CYR61 (Figure 1.12A).  Interestingly, I also found that 
SGK1 overexpression marginally, but not significantly increased TAZ 
transcript, while slightly reducing YAP transcript (Figure 1.12B). This 
result suggests that SGK1 does not strongly affect YAP and TAZ 
transcripts. Therefore, I turned to investigate the mode of YAP and 
TAZ regulation by SGK1 at the post-translational level.
SGK1 stabilizes TAZ via GSK3B inhibition in MCF-10A cells.
In order to scrutinize SGK1 regulation of YAP/TAZ at the 
post-translational level, I treated MG132, a proteasomal inhibitor, in 
SGK1 knockdown MCF-10A cells. Upon treating MG132, due to 
inhibition of proteasome mediated protein degradation, I noticed a 
significant TAZ protein accumulation in SGK1 knockdown set 
comparable to control knockdown set, while in comparison, not much 
change was seen in that of YAP levels (Figure 1.13A).  I reasoned the 
differences between YAP and TAZ in protein accumulation is due to 
fact that TAZ is a versatile protein with a protein half-life of 
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Figure 1-12.  SGK1 enhances CTGF and CYR61 expression in a  
YAP/TAZ-dependent manner.
(A) MCF-10A cells stably expressing either vector or WT SGK1 were 
treated with either control siRNA or combination of siYAP and siTAZ 
(in 1:2 ratio) for 48h were analyzed by Western blot with various 
antibodies. 
(B) MCF-10A cells stably expressing either vector or WT SGK1 treated 




Figure 1-13.  SGK1 stabilizes TAZ protein.
(A) MCF-10A cells stably expressing either shGFP or shSGK1 were 
either treated vehicle (DMSO) or 50 μM MG132 for 6 h and analyzed 
by Western blot. 
(B) MCF-10A cells stably expressing either shGFP or shSGK1 A or 
shSGK1 B was treated with 50 μM MG132 for 6 h and then in vivo 
ubiquitination assay was performed.
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approximately 2h while YAP is relatively a stable protein with a 
half-life of 12h (Liu et al., 2010). Therefore, I decided to focus on 
SGK1 regulation of TAZ from this point on. Next, in order to confirm 
the post-translational regulation of TAZ by SGK1, I performed in vivo
ubiquitination assay in MCF-10A cells that have both been silenced 
with shSGK1 and treated with MG132. In concurrence with the 
previous result in Figure 1.12A, SGK1 knockdown caused an increase 
in poly-ubiquitination of TAZ, suggesting SGK1 stabilizes TAZ from 
ubiquitin mediated protein degradation (Figure 1.13B).  These data 
suggest that SGK1 controls TAZ at the post-translational level.
A　 recent study by Huang et al. suggested TAZ stability can be 
regulated by protein kinases other than LATS1/2 (Huang et al. 2012). 
In their study, Huang et al. suggested that GSK3β is capable of 
destabilizing TAZ, through phosphorylation of the N-terminal residues 
of TAZ (Ser-58 and Ser-62) that are absent in YAP (Huang et al. 
2012). More interestingly, SGK1 is known to inhibit GSK3β by 
phosphorylation in Serine 9 residue of GSK3β (Cohen et al. 2001, 
Sakoda et al. 2003). In order to test the idea that SGK1 stabilizes TAZ 
by phosphorylating and inhibiting SGK1 substrate, GSK3β, I treated 
GSK3β inhibitors, Lithium Chloride or BIO in SGK1 knockdown cells 
(Figure 1.14A-B). Surprisingly, I found that both GSK3β inhibitors 
rescued the SGK1 knockdown phenotype, while BIO is more efficient 
in rescuing TAZ (Figure 1.14A-B). Therefore, I concluded that SGK1 
enhances TAZ stabilization by phosphorylating and inhibiting GSK3β.
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Figure 1-14.  SGK1 stabilizes TAZ protein via SGK1-GSK3β-TAZ 
inhibitory circuit.
(A) MCF-10A cells stably expressing shGFP or shSGK1 were treated 
with GSK3B inhibitor, 25 mM LiCl for 24 h and later analyzed by 
Western blot. 
(B) MCF-10A cells stably expressing shGFP or shSGK1 were treated 




Here I report that SGK1 is a novel downstream target gene of YAP.  
I showed that SGK1 is rapidly upregulated by YAP in a manner that 
resembles SGK1 stimulation to serum.  Moreover, SGK1 upregulation is 
dependent on YAP activation status and YAP’s ability to bind to its 
transcription factor TEAD. Therefore, YAP’s role in transcriptional 
activation of SGK1 is dependent on TEAD. In agreement with these 
data, previous works by Zhao et al. (Zhao et al., 2008) proposed a 
critical role for TEAD in YAP-mediated transcription of its target 
genes. However, even though it seems convincing that TEAD is 
important for SGK1 transcriptional regulation, I have not shown directly 
that TEAD binds to SGK1 enhancer region.  Therefore, further study is 
necessary to be fully confident that TEAD transcription factor is 
required for YAP-mediated SGK1 transcription by chromatin looping. 
Also, epigenetic changes in the SGK1 enhancer, specifically region 
7807 I identified in this study, should be taken into account as well. 
Recent papers by Stein et al. (Stein et al., 2015) revealed that distal 
enhancers controlled by YAP are often marked by H3K27 acetylation. 
Further work is required to confirm that the enhancer region 7807 is 
marked by H3K27 acetylation, mark associated with active transcription.
I also reported that reciprocally, SGK1 upregulates YAP and TAZ. 
In the case of TAZ, it has been shown by Huang et al. (Huang et al., 
2012) that AKT overexpression elevated TAZ level in a dose- 
dependent manner. Since SGK1 and AKT are reported to have 
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functional redundancies due to overlapping kinase substrates, it seems 
plausible to predict that SGK1-mediated molecular phenomenon on 
YAP/TAZ are also valid by AKT. In fact, GSK3β is also substrate for 
AKT. I believe that knocking down both AKT and SGK would result 
in a more drastic phenotype on TAZ stability. In agreement with this 
notion, AKT and SGK1 are homologs of Drosophila　Akt, which has 
been shown to upregulate YAP and TAZ homologs of Drosophila 
Yorkie (Ye et al., 2012).
   Here, I found that the PPxY motif of SGK1 is important for 
upregulation of YAP and TAZ.  Compared to the extent of importance 
stressed on SGK1’s kinase activity, a role of SGK1 PPxY motif is 
often overlooked in this field. Recent studies in the Hippo pathway 
supports the importance of protein-protein interaction between PPxY 
motif and WW domains in mediating cellular phenotypes in both Hippo 
pathway dependent and independent manners (Zhao et al., 2010b, Chan 
et al., 2011). It seems possible that SGK1 may control YAP/TAZ 
activity through its PPxY motif. Further work is required on interaction 
partners of SGK1 in relevance to the Hippo pathway.
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CHAPTER II
Negative regulation of TAZ by YAP
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Abstract
YAP and TAZ are critical effectors of Hippo signaling pathway that 
promote proliferation and cell survival. Although YAP and TAZ are 
commonly regulated by their upstream regulators LATS1/2, they have 
differences in physiological outcomes indicated by their knock-out 
phenotype in mouse models. Here, we report that YAP regulates TAZ 
in a unidirectional mechanism in various cell lines, including normal 
and cancer cells. Utilizing loss of function approaches, we also show 
that TAZ regulation by YAP is not regulated at the transcriptional level 
and post-translational level, but at the translational level. Lastly, we 
show that YAP negative regulation of TAZ is mediated in a Hippo 
pathway-independent manner, implying existence of a novel regulatory 
relationship between YAP and TAZ.
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Introduction
Hippo signaling pathway was originally established in Drosophila 
melanogaster. Hippo pathway consists of a kinase cascade including 
Hippo-Warts, and they are found to enhance cell proliferation while 
suppressing apoptosis (Wu et al., 2003). Yorkie (Yki) was later found to 
be the downstream effector molecule of the Hippo pathway (Huang et 
al., 2005).   Yki is phosphorylated by Warts kinase to allow precise 
binding for 14-3-3. Yki’s binding to 14-3-3 in turn translocates Yki to 
the cytoplasm, thus blocking its nuclear function (Dong et al., 2007). 
The mammalian homologs of Yki are YAP and TAZ. In this sense, 
YAP and TAZ are paralogs to each other.  YAP and TAZ are 
similarly phosphorylated by LATS1/2 kinase, the mammalian homolog 
of Warts, to be sequestered from the nucleus by 14-3-3. As foreseen 
by the dramatic phenotype of Yki-overexpressing flies which exhibit 
massive overproliferation of imaginal discs, YAP and TAZ were also 
found to be potent oncogenes in mammals. YAP overexpression 
promotes hyperproliferation, growth factor independence, 
Epithelial-Mesenchymal Transition (EMT), resistance to apoptosis, and 
ability to form anchorage independent colonies in soft agar, which are 
major hallmarks of cancer (Overholtzer et al., 2006, Hanahan et al., 
2011). Also, YAP overexpressing transgenic mice exhibit rapid and 
marked hypertrophy particularly in the liver and intestine (Camargo et 
al., 2007). Finally, YAP overexpression and nuclear localization of YAP 
was frequently found in many cancers (Steinhart et al., 2008). 
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Therefore, YAP is emerging as an important oncogene that regulates 
multiple aspects of tumorigenesis both in Drosophila and mammals.
TAZ, like YAP, was also initially identified as a 14-3-3 binding 
protein. TAZ has approximately 40~50% sequence similarity to YAP, 
and has common features and domains, namely the WW domain, PDZ 
binding motif, and TEAD binding motif. As described above, YAP 
regulation by Hippo upstream kinases is also conserved in TAZ (Zhao 
et al., 2008b). With regards to tumorigenesis, TAZ is highly expressed 
in various types of cancers, promotes cancer invasion, epithelial to 
mesenchymal transition, and anchorage- independent growth (Chan et 
al., 2008). Therefore, YAP and TAZ function analogously during the 
tumorigenesis.
However, YAP and TAZ have obvious differences in mouse model 
phenotypes. While YAP knockout mouse is embryonic lethal 
(Morin-Kensicki et al., 2006), TAZ knockout mouse is relatively healthy 
except with some problems in the kidney (Hossain et al., 2007). In 
addition, YAP and TAZ have distinct structural features as well. While 
YAP2 isoform has two WW domains, TAZ has only one WW domain. 
YAP has a proline-rich domain in the N-terminus while TAZ does not. 
TAZ has N-terminal phosphodegron targeted by CK1 and GSK3β, 
which YAP lacks (Huang et al., 2012). YAP has a SH3 binding motif 
with which it binds to Yes oncoprotein while TAZ lacks such a 
binding motif. Thus, even though YAP and TAZ are both subject to 
Hippo signaling mediated regulation, there is still a need for a further 
study between YAP and TAZ. 
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In this study, we found that YAP regulates TAZ in non-transformed 
and transformed cells.  We show that YAP regulation of TAZ is 
neither transcriptional nor post-translational,  but rather translational. 
More interestingly, YAP regulation of TAZ was found to be 




MCF-10A was cultured incompleted mediumcontaining DMEM/F12 
media supplemented with 5% horse serum, 20 ng/ml EGF, 0.5 μg/ml 
hydrocortisone, 100 ng/ml cholera toxin, and 10 μg/ml insulin.  RPE 
was cultured in DMEM/F12 media supplemented with 10% FBS.
293T and MDA-MB-231 were cultured in DMEM supplemented with 
10% FBS. MEF　(Mouse Embryonic Fibroblast) was cultured in DMEM 
supplemented with 10% FBS and L-Glutamine 200 μM. All of these 
media contained antibiotics (penicillin/streptomycin).  
For drug treatment, the following compound was used: Cycloheximide 
(100 μM)
Western blot 
Cells were harvested and lysed with RIPA buffer (50 mM Tris-Cl pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholate, 
0.1% SDS) containing protease inhibitors and phosphatase inhibitors (1 
μg/ml Pepstatin A, 1 μg/ml Leupeptin, 1 mM Phenylmethylsulfonyl 
Fluoride, 1 mM Sodium Orthovanadate, 5 mM Sodium Fluoride). 
Western blot analyses were performed using a standard protocol. 
Antibodies
Antibodies used for western blot analysis include: YAP (raised against 
the C-terminal human YAP antigen by Kim et al. (Kim et al., 2015c)), 
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TAZ (Cell Signaling Tech.), ß-actin (Sigma), LATS1 (Cell Signaling 
Tech.), LATS2 (Cell Signaling Tech.), and pLATS1(S1079) (Cell 
Signaling Tech), MST1 (Cell Signaling Tech.), MST2 (Cell Signaling 
Tech.), and CTGF (Santa Cruz Biotech.).
siRNA and sgRNA
Lipofectamine RNAiMAX Reagent (Life Technologies) was used for 
transfection of siRNA. siRNA was prepared and transfected as described 
by the manufacturer. RNA oligonucleotides were synthesized by 
Samchully Pharmaceutical Co. siRNA sequences used in this study are 
siControl (GL2) (CGT ACG CGG AAT ACT TCG A), siYAP 
(GACAUCUUCUGGUCA GAGA), siTAZ (ACGUUG 
ACUUAGGAACUUU). siYAP and siTAZ sequences were obtained 
from Kim et al. (Kim et al. 2015b).
For generation of Knockout cell lines, following sequences were used 
to clone into the lentiCRISPRv2 puro plasmid (Addgene #52961) by 
HaeYon Jeon of Dr. Dae-Sik Lim’s Lab: 
sgLATS2 Forward (CACCGGTAGGACGCAAACGAATCGC), sgLATS2 
Reverse (AAACGCGATTCGTTTGCGTCCTACC), sgLATS1 Forward 
(CACCGGCAACCTAACATACCAGTG), sgLATS1 Reverse 
(AAACCACTGGTATGTTAGGTTGCC).  
After successful cloning, lentiviral sgLATS1 and sgLATS2 were 
transfected with viral packaging/capsid DNA to produce lentivirus.  
After that, lentiviruses were co-infected to MCF-10A and selected with 
puromycin for isolation of LATS1/2 double knockout single clone.
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Quantitative PCR 
RNA preparation and cDNA synthesis were done as described by the 
manufacturer using RiboEx (GeneAll) and M-MLV reverse transcriptase 
(Enzynomics). Quantitative polymerase chain reaction (qPCR) was 
performed using a SYBR green premix reagent (TOPreal qPCR 2X 
PreMIX; Enzynomics) and Bio-Rad CFX Connect instrument. Results 
were analyzed using Microsoft Excel.
Primers used for quantitative PCR are following:
hBeta-actin Forward (CATGTACGTTGCTATCCAGGC), hBeta-actin 
Reverse (CTCCTTAAT GTCACGCACGAT) hYAP Foward 
(GAACCAGAGAATCAGTCAGA), hYAP Reverse 
(GGATTGATATTCCGCATTGC), hTAZ Forward 
(GTCCTACGACGTGACCGAC), and hTAZ Reverse 
(CACGAGATTTGGCTGGGATAC), mGapdh Forward 
(AGGTCGGTGTGAACGGATTTG), mGapdh Reverse 
(TGTAGACCATGTAGTTGAGGTCA), mYap Forward 
(TACTGATGCAGGTACTGCGG), mYap Reverse 
(TCAGGGATCTCAAAGGAGGAC), mTaz Forward 
(CATGGCGGAAAAAGATCCTCC), mTaz Reverse 
(GTCGGTCACGTCATAGGACTG).
Metabolic labeling with radioactive Methionine 
The day before the experiment, MCF-10A cells were transfected with 
either si-Control or si-YAP. The night before the experiment, each 
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MCF-10A cells were split so that cells will be confluent (1~2x107) on 
the day of experiment. On the experiment day, cells were pulse labeled 
with radioactive [35S]Methionine (100 μCi) containing MCF-10A media 
(with dialyzed 5% horse serum and DMEM without L-Methioine and 
L-Cysteine) containing media supplements for 30 min on 37ºC 
chamber. Pulse labeling was processed following a standard protocol 
(Bonifacino et al. 2002). Immediately after collecting cell pellets, cells 
were lysed with RIPA buffer and protein amounts were quantitated. 1 μ
g of anti-TAZ antibody (Santa Cruz Biotech) and 20 μl of Protein A/G 
agarose (GenDEPOT) were used for TAZ immunoprecipitation.
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Results
TAZ is upregulated upon YAP depletion in normal and cancer cells.
We began to investigate the relationship between YAP and TAZ based 
on an unintended observation that TAZ was upregulated in YAP 
depleted cells. In MCF-10A and RPE1 cells that are considered to be 
normal cells, we observed a significant upregulation of TAZ protein 
level upon YAP knockdown, while a significant change in YAP level 
was not seen upon TAZ knockdown (Figure 2.1A-B). Such a Molecular 
phenotype of TAZ increase by YAP depletion was also apparent in 
MDA-MB-231, a malignant breast cancer cell line (Figure 2.1C). 
Moreover, a similar pattern was observed in mouse embryonic fibroblast 
in which Yap was knocked-out (Figure 2.1D). Interestingly, we 
observed a similar pattern of TAZ increase upon YAP knockdown in 
HeLa, MCF-7 and mesenchymal stem cells (Data not shown). 
Therefore, unidirectional YAP regulation of TAZ phenotype was a 
wide-spread molecular phenomenon than initially anticipated.
TAZ upregulation upon YAP depletion is not regulated at the 
transcriptional level.
Next, we pursued on investigating whether YAP negates TAZ at the 
transcriptional level, by measuring the relative TAZ mRNA expression 
upon YAP depletion. We found that TAZ expression was not 
significantly affected by YAP knockdown in MCF-10A, although YAP 
was not effectively knocked-down (Figure 2.2A). To be sure whether 
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Figure 2-1.  TAZ is upregulated in YAP depleted cells.
(A) MCF-10A cells were transfected with either si-Control, si-YAP, or 
si-TAZ for 24h and analyzed by Western blot.
(B) RPE1 cells were transfected with corresponding siRNAs as in (A), 
and analyzed by Western blot.
(C) MDA-MB-231 cells were transfected with corresponding siRNAs as 
in (A-B), and analyzed by Western blot.
(D) Yap flox/flox Taz flox/+ and Yap flox/+ Taz flox/flox mouse 
embryonic fibroblasts were infected with control or Cre-expressing 




Figure 2-2.  TAZ upregulation upon YAP knockdown is not 
significantly controlled at transcriptional level.
(A) MCF-10A cells were transfected with either si-Control or si-YAP 
for a day and then YAP and TAZ transcripts were quantitated by 
qPCR. (n=3)
(B) RPE1 cells were transfected with same siRNAs as in (A), and 
corresponding mRNAs were quantitated by qPCR. (n=3)
(C) MDA-MB-231 cells were transfected with same siRNAs as in 
(A-B), and then YAP and TAZ mRNAs were quantitated by qPCR. 
(n=3)
(D) Yap flox/flox Taz flox/+ MEF were treated with either control or 
Cre virus for 48h and then selected with puromycin. After that, Yap 
and Taz mRNAs were analyzed by qPCR.  Data are means 
±SD;*p<0.05; **p<0.01; ***p<0.001; N.S. Not statistically significant.
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the TAZ phenotype we saw in MCF-10A was reproducible in other 
cell lines, we checked TAZ mRNA expression changes upon YAP 
knockdown in RPE1 and MDA-MB-231 cells. As expected, we obtained 
similar results in TAZ mRNA levels in YAP-depleted RPE1 and 
MDA-MB-231 cells (Figure 2.2B-C). Furthermore, Yap flox/flox Taz 
flox/+ MEF stably expressing Cre (which is virtually same as Yap 
Knockout), showed a consistent result as previous figures in that YAP 
does not significantly affect TAZ at the transcription level (Figure 
2.2D). Interestingly, we realized that there are several papers published 
that supports our finding. For example, Xin et al. (Xin et al., 2013) 
showed that Yap conditional knockout heart does not lead to a 
statistically significant change in Taz mRNA expression. On the other 
hand, our result is surprising, considering the other group’s report that 
overexpression of YAP reduces TAZ mRNA in a TEAD-dependent 
manner (Moroishi et al., 2015). A　possible discrepancy may arise due 
to differences between loss of function and gain of function 
experiments. Therefore, YAP regulation of TAZ is, at least in　the loss 
of function context, not significantly regulated at the transcriptional 
level. 
TAZ upregulation upon YAP knockdown is regulated at the 
translational level.
Next, we wanted to analyze at which level in central dogma of 
molecular biology, YAP negatively regulates TAZ. In order to test 
whether YAP regulates TAZ at the post-translational level, we 
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Figure 2-3.  TAZ upregulation upon YAP depletion is not mediated by 
TAZ stabilization, but rather, in control of TAZ translation.
(A) Control or YAP knockdown MCF-10A cells were chased with 
Cycloheximide for indicated time points. ß-actin loading was adjusted to 
detect approximately equal amounts of TAZ at t = 0.
(B) Control or YAP knockdown MCF-10A cells were metabolically 
labelled for 30min and quantitated by image J.
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performed cycloheximide chase experiment in control and YAP 
knocked-down cells. Cycloheximide is a translational inhibitor commonly 
utilized to acquire information about protein half-life. Thus, if YAP 
knockdown results in TAZ protein stabilization, one would expect 
elongated half-life of TAZ. However, the result was that there was 
virtually no difference in TAZ between control and YAP knocked-down 
sets (Figure 2.3A). Therefore, YAP seems to regulate TAZ neither at 
the transcriptional, nor post-translational level. Now, since we are left 
with translational level control to test, we performed metabolic pulse 
chase experiment with si-control and si-YAP transfected MCF-10A to 
investigate whether YAP regulates biosynthesis of TAZ protein. We 
chose Methionine as a radiolabeled amino acid of choice, because TAZ 
protein contains a sufficient number of Methionine (18 out of 404 
amino acids; roughly 4.5 % of amino acid composition). When we 
performed the metabolic labeling experiment, we found that in YAP 
knockdown cells, TAZ biosynthesis rate was increased by approximately 
1.95 fold (Figure 2.3B). Thus, we concluded that TAZ increase in YAP 
depletion was due to acceleration of TAZ biosynthesis.
TAZ up-regulation upon YAP depletion is regulated independent of 
Hippo signaling pathway.
Lastly, we examined YAP regulation of TAZ in the context of Hippo 
pathway. Since MCF-10A is considered to be one of the model cell 
lines useful for examining Hippo components, we focused our 
mechanistic study in MCF-10A. When we knocked-down YAP or TAZ 
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in MCF-10A and observed for any change in core Hippo kinase 
components, MST1/2 and LATS1/2, there was no obvious change in 
their amounts or activity (Figure 2.3A). Hypothetically speaking, if YAP 
negatively regulates TAZ through their upstream kinase LATS1/2, we 
expected a reduction in LATS1/2 activity represented by reduction in 
Serine 1079 phosphorylation. However, there was no change in 
LATS1/2 activity. In contrast, protein amounts of LATS1 and 2 were 
elevated in either YAP or TAZ knocked-down cells (Figure 2.4A). In 
order to distinguish whether YAP regulation of TAZ is only evident in 
certain context, we observed TAZ upregulation by YAP knockdown in 
Hippo pathway active verses inactive context represented by high versus 
low cell density, respectively. Intriguingly, YAP knockdown resulted in 
an increase of TAZ protein levels in both high and low density 
conditions, indicating Hippo pathway independent regulation of TAZ by 
YAP (Figure 2.4B). In order to validate that canonical Hippo pathway 
regulation of TAZ is dispensible for YAP regulation of TAZ, we 
knocked-out both LATS1 and LATS2 in MCF-10A by lentiCRISPR 
system. We found that when YAP is knocked-down in LATS1/2 
knockout context, TAZ-upregulation by YAP-knockdown phenotype was 
still functional, shown by a marked increase in TAZ protein level 
(Figure 2.4C). Moreover, when 5SA YAP was overexpressed in 
LATS1/2 Knockout context, we still observed downregulation of TAZ 
by YAP overexpression (Figure 2.4D). In conclusion, TAZ regulation 
by YAP is mediated by a canonical Hippo pathway independent 
mechanism.
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Figure 2-4.  TAZ upregulation upon YAP knockdown is not mediated 
by Hippo signaling pathway.
(A) MCF-10A cells were transfected with indicated siRNAs for 24h 
and then cells were harvested for Western blot analysis with antibodies 
against Hippo related proteins.
(B) MCF-10A cells were transfected with same siRNAs as in (A), and 
then split into varying densities.  After overnight incubation, cells were 
analyzed by Western blot.
(C) Stable cells of control or LATS1/2 Knockout were either 
transfected with si-Control or si-YAP for 24h and then analyzed by 
Western blot.
(D) Western blot analysis of control and LATS1/2 Knockout cells 




Here, we found that TAZ is negatively regulated by its paralog, 
YAP. We also found that although YAP regulates TAZ, TAZ 
does not regulate YAP, meaning a unidirectional regulation exists 
between YAP and TAZ. Actually, while we were mid-way 
through this project, a paper by Finch-Edmondson et al., 
(Finch-Edmondson et al., 2015) reported the same observation of 
TAZ regulation by YAP in a unidirectional mechanism. Therefore, 
our observation was confirmed to be consistent and reproducible 
by other researchers. However, another group of scientists 
reported that YAP and TAZ bi-directionally regulate each other 
(Moroishi et al., 2015).  In their study, Moroishi et al. utilized a 
gain of function approach to persuasively show that hyperactive 
YAP overexpression represses TAZ while hyperactive TAZ 
overexpression repressed YAP in cell culture systems. Meanwhile, 
Finch-Edmondson et al. utilized wildtype TAZ using an inducible 
overexpression system to show that YAP levels were unaffected.
Next, we have discovered that YAP does not regulate TAZ at 
the transcriptional level.  To confirm this, we used multiple types 
of cell lines, including non-transformed and transformed, of 
human and mouse. And we consistently found that levels of 
human TAZ mRNA or mouse Taz mRNA were not significantly 
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affected by human YAP knockdown or mouse Yap knockout, 
respectively. These results are in sharp contrast to the report by 
Moroishi et al., in which they show hyperactive YAP repression 
of TAZ is abolished by mutation of the TEAD binding site to a 
defective form. There is certainly an issue concerning gain of 
function and loss of function experiments, in which dramatic 
changes in cellular environment may result incongruous cellular 
outcomes. Therefore, further study is required to clearly elucidate 
such context-dependent changes in regulatory relationship between 
YAP and TAZ.          
Moreover, in contrast to Moroishi et al.’s claim that YAP 
regulation of TAZ is a Hippo dependent phenomenon, we 
obtained an opposite result which shows that TAZ regulation of 
YAP occurs independent from LATS1/2. One obvious difference 
between their result and ours is that they used mouse embryonic 
fibroblasts while we used MCF-10A cells as a model system to 
knock out LATS1/2. Further work is required to untangle this 
species-specific differences in the LATS1/2 KO phenotype.
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국 문 초 록
갈수록 복잡해지는 암 생물학계에서 최근 관심을 끄는 YAP
과 TAZ 의 역할들을 볼 때, YAP과 TAZ의 주변 단백질 네트
워크를 더욱 명확히 연구하는 것이 요구된다. 다시 말하면, 이
미 잘 알려진 Hippo 신호전달체계에서의 YAP/TAZ 관련 세
부적 조절 기작들을 밝히는 것이 YAP과 TAZ의 암 발달에서
의 역할 정도를 이해하는 데에도 도움이 된다.
그러므로 나는 YAP과 TAZ 의 후보 조절인자들에 대한 연구
를 진행하였다. SGK1은 PI3-K 신호전달체계의 종양단백질로
서, AKT 억제제에 저항성을 띄는 암세포에서 과발현되는 중
요한 타겟 유전자로 최근에 알려졌다. 나는 SGK1이 YAP의
활성도에 빠른 반응도를 가진 YAP의 타겟 유전자인 것으로
확인하였다. 또한, SGK1의 전사 과정이 YAP의 중요한 전사
인자인 TEAD에 의하여 조절 받는다는 것을 밝혔다. 추가적으
로 YAP이 SGK1의 distal enhancer에 붙어서 SGK1 의 전사
를 유도한다는 것을 확인했다.
한편으로 나는 YAP과 TAZ의 활성을 조절할 수 있는 SGK1
의 새로운 기능을 발견을 했다. SGK1은 YAP과 TAZ의 잘 알
려진 타겟 유전자들인 CTGF와 CYR61을 조절하며 이때,
SGK1의 kinase domain 과 PPxY motif가 관여한다는 것을 밝
혔다. SGK1는 더 나아가 YAP과 TAZ를 통하여 CTGF와
CYR61를 조절한다. 마지막으로, 나는 SGK1이 TAZ 단백질을
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안정화시키기 위하여 SGK1의 substrate인 GSK3β를 인산화
시킨다는 것을 확인하였다. 그러므로 나는 SGK1이 YAP/TAZ
의 새로운 positive regulator 라는 것을 밝혔다.
그에 반해, 나는 YAP이 paralog인 TAZ를 억제한다는 것을
발견했다. 우리는 이 조절이 단일방향이며 malignant
transformation 여부와 상관없이 여러 종류의 세포주에서 보존
된 조절이라는 것을 확인하였다. 또한 이러한 YAP에 의한
TAZ 억제는 central dogma의 번역영역에서 조절된다는 것을
밝혔다. 그리고 나는 이 조절 기작이 Hippo 신호조절체계와는
무관하다는 것을 확인했다.
결론적으로 나는 이 연구를 통해 TAZ를 활성화시키고 또 억
제시키는 두 종류의 조절 기작을 발견하였다.
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